Tositumomab: Difference between revisions

David Canner (talk | contribs)
No edit summary
David Canner (talk | contribs)
No edit summary
 
Line 20: Line 20:
! 167000
! 167000
! 205800
! 205800
! Ibritumomab
! 67000
|-
|-
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
Line 32: Line 32:
! 68
! 68
! 206
! 206
! Ibritumomab
! 108
|-
|-
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
Line 38: Line 38:
! 32939000
! 32939000
! Rituximab
! Rituximab
! Ibritumomab
! 17000
|-
|-
! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h)
! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h)

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

David Canner